Oramed Pharmaceuticals: Funding, Investors & Team (Sep 2026)

Oramed Pharmaceuticals (NASDAQCM:ORMP) was established in 2006 and is based on extensive medical research conducted at Hadassah University Medical Center in Jerusalem, Israel over a period of 30 years. The research was led by Professor Hanoch Bar-On at Hadassah Hospital's Diabetes Unit, with the aim of developing a technology that would allow insulin to be administered orally to individuals with diabetes. In 2005, a significant medical breakthrough paved the way for the creation of Oramed Pharmaceuticals, in which Hadassah remains a partial owner. Professor Bar-On, along with Dr. Miriam Kidron, co-founded the company, and Professor Bar-On served as a director until his untimely death in 2006. Oramed has been successful in conducting various animal and human studies to test its technology on its flagship products, an oral insulin capsule named ORMD-0801, and an oral exenatide capsule called ORMD-0901, which is a GLP-1 Analog. The combination therapy of ORMD-0801 and ORMD-0901 has shown promising results in pre-clinical trials, and clinical trials are expected to follow. Oramed's unique oral delivery technology can also serve as a platform for other vaccines and medications that are currently administered through injections. Many pharmaceutical companies, both large and small, have approached Oramed to test the compatibility of their products with Oramed's technology. The company has attracted renowned scientists to its scientific advisory board, including former Senior VP of Pfizer, Dr. Michael Berelowitz; Prof. John Amatruda, former Senior VP of Merck and Co.; Prof. Ele Ferrannini, Past President of the EASD; and Prof. Avram Hershko, a Nobel Prize Laureate in Chemistry. Oramed has received continual support from the Office of the Chief Scientist of Israel, which has awarded the company multiple grants for its research. Recent developments for Oramed include the approval of five patents for its technologies by the Israeli, Japanese, Australian, and New Zealand Patent Offices. These patent approvals validate Oramed's technology and establish a strong international presence for its oral protein delivery methods. The company also has 34 remaining patent applications awaiting approval, and expects more patents to be granted in the future.

Oramed Pharmaceuticals has raised $102M across 1 round on record. The most recent is an undisclosed round of $102M announced in Sep 2023.

Oramed Pharmaceuticals' most recent funding round on record is an undisclosed round of $102M, announced in Sep 2023.

Nadav Kidron is listed as CEO at Oramed Pharmaceuticals.

Oramed Pharmaceuticals is based in New York, United States.

Oramed Pharmaceuticals is in the 11-50 employee band.

Oramed Pharmaceuticals' latest round of $102M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.